[{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Knight Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Estradiol","moa":"||Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"TherapeuticsMD","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TherapeuticsMD \/ TherapeuticsMD","highestDevelopmentStatusID":"15","companyTruncated":"TherapeuticsMD \/ TherapeuticsMD"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Segesterone Acetate","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"TherapeuticsMD","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"TherapeuticsMD \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TherapeuticsMD \/ Inapplicable"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Rubric Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Steroid","year":"2022","type":"Financing","leadProduct":"Segesterone Acetate","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"TherapeuticsMD","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"TherapeuticsMD \/ Rubric Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"TherapeuticsMD \/ Rubric Capital Management"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2021","type":"Public Offering","leadProduct":"Estradiol","moa":"||Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"TherapeuticsMD","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"TherapeuticsMD \/ Cantor Fitzgerald","highestDevelopmentStatusID":"15","companyTruncated":"TherapeuticsMD \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Mayne Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2023","type":"Licensing Agreement","leadProduct":"Estradiol","moa":"||Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"TherapeuticsMD","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"TherapeuticsMD \/ Mayne Pharma","highestDevelopmentStatusID":"15","companyTruncated":"TherapeuticsMD \/ Mayne Pharma"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Mayne Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"AUSTRALIA","productType":"Hormone","year":"2022","type":"Agreement","leadProduct":"Estradiol","moa":"||Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"TherapeuticsMD","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"TherapeuticsMD \/ TherapeuticsMD","highestDevelopmentStatusID":"15","companyTruncated":"TherapeuticsMD \/ TherapeuticsMD"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2020","type":"Public Offering","leadProduct":"Estradiol","moa":"||Estrogen-alpha receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"TherapeuticsMD","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"TherapeuticsMD \/ Cantor Fitzgerald","highestDevelopmentStatusID":"15","companyTruncated":"TherapeuticsMD \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Nurx","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Agreement","leadProduct":"Segesterone Acetate","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"TherapeuticsMD","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"TherapeuticsMD \/ TherapeuticsMD","highestDevelopmentStatusID":"15","companyTruncated":"TherapeuticsMD \/ TherapeuticsMD"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Segesterone Acetate","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"TherapeuticsMD","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"TherapeuticsMD \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TherapeuticsMD \/ Inapplicable"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Segesterone Acetate","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"TherapeuticsMD","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Vaginal Insert","sponsorNew":"TherapeuticsMD \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"TherapeuticsMD \/ Inapplicable"},{"orgOrder":0,"company":"TherapeuticsMD","sponsor":"Afaxys Pharma","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Steroid","year":"2020","type":"Agreement","leadProduct":"Segesterone Acetate","moa":"||Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"TherapeuticsMD","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TherapeuticsMD \/ TherapeuticsMD","highestDevelopmentStatusID":"15","companyTruncated":"TherapeuticsMD \/ TherapeuticsMD"}]

Find Clinical Drug Pipeline Developments & Deals by TherapeuticsMD

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Imvexxy (estradiol vaginal inserts) is approved in the U.S. for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.

                          Product Name : Imvexxy

                          Product Type : Hormone

                          Upfront Cash : $140.0 million

                          March 01, 2023

                          Lead Product(s) : Estradiol,Inapplicable

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved FDF

                          Sponsor : Mayne Pharma

                          Deal Size : $225.7 million

                          Deal Type : Licensing Agreement

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : The sNDA included minor revisions to Annovera (segesterone acetate) in vitro release testing specification that allowed for normal manufacturing variability, was approved by the FDA in August 2018 as the only long-lasting, reversible, procedure-free birt...

                          Product Name : Annovera

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          May 20, 2022

                          Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Imvexxy (estradiol vaginal inserts) is approved in the U.S. for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy (VVA), due to menopause.

                          Product Name : Imvexxy

                          Product Type : Hormone

                          Upfront Cash : $140.0 million

                          April 12, 2022

                          Lead Product(s) : Estradiol,Inapplicable

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved FDF

                          Recipient : Mayne Pharma

                          Deal Size : $225.7 million

                          Deal Type : Agreement

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : TherapeuticsMD has three growing assets whose value has been enhanced by the recent approval of both Annovera’s (segesterone acetate) supplemental NDA and lower-dose Bijuva, as well as the increasing relevance of convenient and safe contraceptive optio...

                          Product Name : Annovera

                          Product Type : Steroid

                          Upfront Cash : Undisclosed

                          January 08, 2022

                          Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved FDF

                          Sponsor : Rubric Capital Management

                          Deal Size : $15.0 million

                          Deal Type : Financing

                          blank

                          05

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : TherapeuticsMD intends to use the net proceeds from the offering for commercialization of its three FDA-approved products, IMVEXXY® (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual acti...

                          Product Name : Imvexxy

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          November 02, 2021

                          Lead Product(s) : Estradiol,Inapplicable

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved FDF

                          Sponsor : Cantor Fitzgerald

                          Deal Size : $110.0 million

                          Deal Type : Public Offering

                          blank

                          06

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : TherapeuticsMD intends to use the net proceeds from the offering for commercialization of its three FDA-approved products which includes IMVEXXY®, BIJUVA® and ANNOVERA®, and for working capital and general corporate purposes.

                          Product Name : Imvexxy

                          Product Type : Hormone

                          Upfront Cash : Undisclosed

                          October 11, 2020

                          Lead Product(s) : Estradiol,Inapplicable

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved FDF

                          Sponsor : Cantor Fitzgerald

                          Deal Size : $30.0 million

                          Deal Type : Public Offering

                          blank

                          07

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : BIJUVA is a once-daily combination of estradiol and progesterone in a single oral capsule that will be available in two strengths in Canada indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause in women with an in...

                          Product Name : Bijuva

                          Product Type : Hormone

                          Upfront Cash : Inapplicable

                          September 21, 2020

                          Lead Product(s) : Estradiol,Progesterone

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved FDF

                          Recipient : Knight Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : The agreement is aimed at expanding access to ANNOVERA® (segesterone acetate and ethinyl estradiol vaginal system), a first of its kind annual birth control ring. ANNOVERA is the first FDA-approved long-lasting birth control method that does not require...

                          Product Name : Annovera

                          Product Type : Steroid

                          Upfront Cash : Undisclosed

                          July 15, 2020

                          Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Approved FDF

                          Recipient : Nurx

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          09

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          February 28, 2020

                          Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol,Itraconazole,Rifampicin

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          February 17, 2020

                          Lead Product(s) : Segesterone Acetate,Ethinyl Estradiol,Tampon

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank